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Background: Severe complicated intra-abdominal sepsis (SCIAS) has high mortality, thought due in part to
progressive bio-mediator generation, systemic inflammation, and multiple organ failure. Treatment includes early
antibiotics and operative source control. At surgery, open abdomen management with negative-peritoneal-pressure
therapy (NPPT) has been hypothesized to mitigate MOF and death, although clinical equipoise for this operative
approach exists. The Closed or Open after Laparotomy (COOL) study (https://clinicaltrials.gov/ct2/show/NCT03163095)
will prospectively randomize eligible patients intra-operatively to formal abdominal closure or OA with NPTT. We
review the ethical basis for conducting research in SCIAS.
Main body: Research in critically ill incapacitated patients is important to advance care. Conducting research among
SCIAS is complicated due to the severity of illness including delirium, need for emergent interventions, diagnostic
criteria confirmed only at laparotomy, and obtundation from anaesthesia. In other circumstances involving critically ill
patients, clinical experts have worked closely with ethicists to apply principles that balance the rights of patients whilst
simultaneously permitting inclusion in research. In Canada, the Tri-Council Policy Statement-2 (TCPS-2) describes six
criteria that permit study enrollment and randomization in such situations: (a) serious threat to the prospective
participant requires immediate intervention; (b) either no standard efficacious care exists or the research offers realistic
possibility of direct benefit; (c) risks are not greater than that involved in standard care or are clearly justified by
prospect for direct benefits; (d) prospective participant is unconscious or lacks capacity to understand the complexities
of the research; (e) third-party authorization cannot be secured in sufficient time; and (f) no relevant prior directives are
known to exist that preclude participation. TCPS-2 criteria are in principle not dissimilar to other (inter)national criteria.
The COOL study will use waiver of consent to initiate enrollment and randomization, followed by surrogate or proxy
consent, and finally delayed informed consent in subjects that survive and regain capacity.
Conclusions: A delayed consent mechanism is a practical and ethical solution to challenges in research in SCIAS. The
ultimate goal of consent is to balance respect for patient participants and to permit participation in new trials with a
reasonable opportunity for improved outcome and minimal risk of harm.
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Patients with severe sepsis and multiple organ dys-
function have a high mortality rate; their care is expen-
sive [1, 2]. Sepsis is a common cause of death worldwide
[3, 4], with an increasing incidence estimated at between
18 and 31 million cases worldwide per year [4–8]. Mor-
tality approaches 30–40% when shock is present [9–11],
and is higher in countries without advanced acute care
hospitals with fully resourced intensive care units [3].
Sepsis management is a tremendous burden to society;
in the USA, it ranked highest among admissions for all
disease states, accounted for more than $24 billion in
hospital expenses in 2013, represented 13% of total hos-
pital costs, yet accounted for only 3.6% of hospital length
of stays [12, 13].
Severe complicated intra-abdominal sepsis (SCIAS) is
a particular challenge as early surgical source control
should be part of initial therapy [14]. Because of progres-
sive inflammation, SCIAS frequently progresses to septic
shock, multiple organ dysfunction, and often death [15].
Inflammation associated with intra-abdominal sepsis
may result in significant ‘third-spacing’ of fluid, and de-
velopment of raised abdominal pressure further affecting
cardiopulmonary and renal function. The commonly ac-
cepted surgical approach at completion of a (source con-
trol) laparotomy is to close the abdominal wall fascia in
a manner similar to any other surgical procedure with-
out contemplating the unique biological and inflamma-
tory mechanisms in SCIAS and the consequences of
intra-abdominal hypertension. An alternate surgical ap-
proach for SCIAS is to leave the abdominal cavity ‘open’,
applying (through various techniques) negative pressure
therapy within the peritoneal cavity [16]. The ‘open’ sur-
gical approach has been widely adopted based on basic
science data which suggests this prevents dysregulated
inflammation, encouraging but preliminary human stud-
ies [17–19]. Both approaches are used, and each ap-
proach may have unique benefits and risks. There is a
lack of consensus and equipoise on which approach is
more efficacious. There is a need for methodologically
rigorous clinical trials to compare ‘open’ versus ‘closed’
surgical management [20].
The Closed or Open after Laparotomy (COOL) study
is a multinational randomized controlled clinical trial
comparing an ‘open abdomen’ (OA) approach to closed
surgical management (https://clinicaltrials.gov/ct2/show/
NCT03163095). The University of Calgary is both the
sponsoring institution and the pilot centre. The original
ethics submission was made to the Conjoint Health
Research Ethics Board of the University of Calgary: the
CHREB must follow all human research regulations
under Canadian Law and The Tri-Council Policy
Statement-2. It also complies with The International
Conference for Harmonisation (ICH) Guidance E6: theGood Clinical Practice (GCP) guideline. However, the
COOL trial is an international collaboration involving
investigators, medical centres, and medicolegal systems
across many different countries. Recognizing that there
is a gross global imbalance in the funding directed to a
disease that affects patients irrespective of country/
health system [21, 22], the COOL trial will attempt to
encourage global participation. Thus, this review will
discuss the relevant principles of performing emergency
research in critically ill surgical patients in general and
as they specifically apply to the COOL study.
Research ethics and informed consent
The necessity of informed consent for participation in
research arises from one of the darkest parts of modern
medical profession’s history, and also one of its most en-
lightening. In the early to mid-twentieth century, there
were egregious examples of research involving humans
where informed consent was not obtained and individ-
uals suffered serious and significant harm including
death [23, 24]. Attention has rightly been focused on the
horrors of concentration camps operated by the Nazi re-
gime in Germany and the occupied countries. In these
concentration camps were repeated examples of experi-
mentation on human subjects including research on
hypothermia, extreme starvation, wound management,
and eugenics. Following the Second World War, the tri-
als of Nazi medical personnel at Nuremburg informed
the world of some of these atrocities and resulted in the
Nuremburg Code [23, 24]. The first of the 10 points of
the Nuremburg Code stated ‘Required is the voluntary,
well-informed, understanding consent of the human
subject in a full legal capacity.’ The remaining nine
points identified principles that are also important (and
relevant for surgical research) including a biological
basis that justifies the research, minimizing risk, a bal-
ance of risk and benefit, protection of participant’s well-
being, a necessity to stop an individual’s participation if
unduly dangerous, and the requirement to permit a sub-
ject’s withdrawal of consent [23, 25, 26]. In 1964, The
World Medical Association adopted the Declaration of
Helsinki, which emphasized the fundamental right of
self-determination practically manifest as consent being
the right to make informed decisions [25, 27, 28]. The
Declaration also identified that informed consent may be
provided by a person other than the subject if the sub-
ject themselves was not capable [28].
Despite the Code and the Declaration, ongoing evidence
of research malfeasance continued. In the late 1920s,
sharecroppers in the USA were recruited for a study to
examine the natural history of syphilis (Tuskegee Syphilis
Study): this study continued until it was exposed in the
media in the late 1960s [23]. In 1966, Henry Beecher pub-
lished a case series of clinical research studies with glaring
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seem to be breaches of ethical conduct in experimentation
are by no means rare…examples could be easily found…’
[23]. Arising from Beecher’s report, and other examples
such as the Tuskegee Syphilis study, the National
Commission for the Protection of Human Subjects of
Biomedical and Behavioral Research met, and in 1978
issued the ‘Belmont Report: Ethical Principles and
Guidelines for the Protection of Human Subjects of
Research.’ [29]. The Belmont Report emphasized 3 key as-
pects of research ethics: respect for persons (autonomy),
beneficence (maximizing benefits and minimizing harms),
and justice (fair distribution of risks/benefits/costs in a
non-exploitive manner). The application of these princi-
ples emphasized the selection of subjects, a risk-benefit as-
sessment, and informed consent [29, 30]. Critiques of the
Belmont Report include that the 3 principles are not pre-
sented in a ‘weighted’ manner, i.e. that a principle such as
respect for persons should have primacy [31]. In response,
at least one member of the panel, Dr. Al Jonsen, stated
that it is the responsibility of individual (investigators) and
institution review boards to evaluate each research pro-
posal uniquely and apply the principles appropriate to the
proposed research [32]. The Nuremburg Code, the
Declaration of Helsinki, and the Belmont Report form a
historical basis for current national and international re-
search standards.
For example, The International Conference for
Harmonization (ICH) Guidance E6: the Good Clinical
Practice (GCP) Consolidated Guidelines [33] has its
roots in the Declaration of Helsinki and focuses on the
protection of research subjects and the credibility and
validity of research findings. It is an accepted standard
in many countries (such as Canada, the European Union,
Japan, Australia, and the USA) as a definitive quality
standard of conducting clinical trials for pharmaceutical
research. ICH GCP guidelines include expectations of
institutional research boards/research ethics boards re-
lated to board composition, protocol review, and pro-
cesses related to consent. Although ICH GCP guidelines
only pertain to pharmaceuticals and these guidelines are
not necessarily part of the regulations of individual coun-
tries, the GCP has become a widely adopted pragmatic
standard. Institutions, such as hospitals or universities
with medical schools, where pharmaceutical research is
conducted have IRB’s/REB’s which must adhere to the
principles of the guidelines; as such, they have become in
many ways de facto applied to most human-based clinical
research. This GCP includes provisions on processes when
consent cannot be obtained from study participants or
their legally authorized representatives (E6 (R2) 4.8.15).
Research funded by US government agencies are gov-
erned by ‘The Common Rule’ or the Department of
Health and Human Services ‘Federal Policy for theProtection of Human Participants (45 CFR 46, Subpart A)’.
The Belmont Report serves as the basis for The Common
Rule which defines the basic principles of research ethics
involving human participants. In 2001, Canada’s three fed-
eral research agencies, the Canadian Institute for Health
Research (CIHR), the Natural Sciences and Engineering
Research Council of Canada (NSERC), and the Social
Sciences and Humanities Research Council (SSHRC),
jointly created the Interagency Advisory Panel on Research
Ethics (PRE or the Panel) as part of a collaborative effort to
promote the ethical conduct of research involving human
participants [34]. The Advisory Panel has published the
Tri-Council Policy Statement-2 which provides require-
ments for institutions who conduct human-based research
and receive funding from one of these agencies.
All of these guidelines and policies emphasize, in keep-
ing with the principle of Respect for Persons, that at en-
rolment, participant consent is expected as a normative
standard. However, these also recognize and support
that there are exceptions to this general ethical require-
ment which apply in specific situations such as emer-
gency research [34, 35]. Across all of these guidelines or
regulations is an acceptance that research should be in-
clusive and that research in emergency situations may
provide life-saving benefits, and therefore, consent pro-
cesses have to be developed and implemented to permit
research in emergency setting where consent cannot be
obtained. In emergency research, potential participants
may not have the capacity to provide informed consent
at enrolment. Under these circumstances, patients are
considered particularly vulnerable and are owed special
ethical obligations and protection commensurate with
the risks involved. The research participant’s welfare
should be protected by additional safeguards, where
feasible and appropriate [34].
Clinical equipoise
A major ethical tenet underlying all clinical research but
in particular randomized clinical trials has been the
concept of clinical equipoise perhaps best classically for-
mulated by Benjamin Freedman. Freedman defined equi-
poise as ‘genuine uncertainty within the expert medical
community—not necessarily on the part of the individ-
ual investigator—about the preferred treatment.’ Al-
though many criticisms have been put forward as to the
appropriateness of equipoise as a sole justification for
proceeding with a clinical trial, once a decision has been
made on a broader context to proceed with a clinical
trial, clinical equipoise maintains import in that it helps
to sharpen focus on whether study treatment arms are
reasonably comparable. Furthermore, equipoise places
emphasis on informing patients on the honest disagree-
ment among expert clinicians as to which therapy is
proven or a matter of professional preference [36]. If
Table 1 Required Criteria for Medical Emergencies carried out
without the consent of participants
a. A serious threat to the prospective participant requires immediate
intervention;
b. Either no standard efficacious care exists or the research offers a
realistic possibility of direct benefit to the participant in comparison
with standard care;
c. Either the risk is not greater than that involved in standard efficacious
care, or it is clearly justified by the prospect for direct benefits to the
participant;
d. The prospective participant is unconscious or lacks capacity to
understand the risks, methods and purposes of the research project;
e. Third-party authorization cannot be secured in sufficient time, despite
diligent and documented efforts to do so; and
f. No relevant prior directive by the participant is known to exist.
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larly, if both are already commonly used (i.e. a trial of 2
accepted forms of [surgical] therapy) then equipoise is
also relevant for considering the ethical propriety of wai-
ver or deferral of consent. Criticisms with this principle
include that it is often narrowly interpreted within only
a clinical context, rather than in a broader societal inter-
est in evidence-based policy. Gamble commented on the
irony that informed consent is not required for treat-
ment with non-validated therapies that are currently in
practice but for which there is a lack of evidence in the
benefits and risks [37].
The exigency pressing necessity for high quality
surgical research
In general, the overall quality of surgical research has
been criticized as being grossly inadequate to properly
guide scientifically informed decision making despite the
importance these decisions have in determining whether
patients die or are permanently impaired from surgical
emergencies [38, 39]. One famous commentary com-
pared surgical research to ‘comic opera’ [40], lamenting
the reliance on retrospective case series as a method-
ology, and another referred to the typical retrospective
case series as ‘research waste’ [38]. However, it has been
countered that surgical research is difficult to properly
conduct as there are so many practical barriers to con-
ducting RCTs especially in urgent life-threatening situa-
tions [41], and thus, RCTs make up only a small
proportion of published surgical research [38, 39]. Retro-
spective case series predominate, potentially because
they are vastly easier to conduct and are free of regula-
tory hurdles that accompany conducting an RCT, but
are still publishable in journals and offer career advance-
ment to investigators. Further, RCTs are not required by
device manufacturers or regulators to allow market entry
[38]. Unfortunately, medical history is replete with
examples of where non-randomized, biased research
provided misinformation that led to worse clinical out-
comes, because the more difficult but required RCTs
were not performed [42, 43].
Consent processes for SCIAS and the COOL trial in
Canada
The COOL trial will be conducted across the globe and
thus will involve multiple countries, hospitals, cultures,
and medicolegal systems. The COOL investigators
assessed that a priori informed consent from potential
participants was impractical because (1) inclusion
criteria could only be identified in the operating room,
(2) there was not a reasonable way to identify potential
participants preoperatively and reviewing ‘possible’
enrolment could reasonably be confused/conflated with
consent for the clinical operative consent, and (3)consent within the operating room could not feasibly be
obtained from a legally authorized representative with-
out the risk for an unacceptable significant delay in a
potentially unstable patient. Therefore, a decision was
made to seek approval from our CHREB to use delayed
or deferred consent as the COOL trial met the alter-
ations on consent requirements described in article 3.8a
of the TCPS2 (Table 1) [34].
Requirement 1
A serious threat to the prospective participant requires
immediate intervention;
Sepsis is unpredictable and deadly with sudden onset,
and intra-abdominal sepsis is one of its most complicated
forms [44–46]. Mortality in SCIAS approaches 30–40%
when shock is present [9, 11], and this may be 80% in the
developing world [3]. Once identified, such patients re-
quire immediate surgical intervention. The failure to
promptly obtain adequate source control has been de-
scribed as an independent predictor of mortality in those
with this condition [47]. Thus, any delay in treatment,
even to ensure informed consent, could slow the patients
care and negatively impact their care and outcomes. Simi-
lar to the hemorrhaging patient, the septic patient needs
immediate management and it is because of the urgent re-
quirement for treatment that it is impossible or impractic-
able to obtain consent prior to treatment.
Requirement 2
No standard efficacious care exists or the research offers
a realistic possibility of direct benefit to the participant
in comparison with standard care;
Requirement 3
Risk is not greater than that involved in standard effica-
cious care, or it is clearly justified by the prospect for
direct benefits to the participant;
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strategies both of which are considered a standard of care
for SCIAS; as such, either treatment allocation may carry
unique risks or benefits, but that there is an equipoise as
to a preferred management approach [48, 49]. Neither of
the treatment allocation arms, open or closed manage-
ment, are new or novel. Despite being of more recent
interest, the use of the OA technique historically dates
back at least 75 years [50]. The closed management
strategy is the common approach for the vast majority of
elective and urgent abdominal surgical procedures. Its
adoption for SCIAS has not considered the unique inflam-
matory consequences of this condition, including the de-
velopment of intra-abdominal hypertension/abdominal
compartment syndrome, and the contribution of un-
drained inflammatory mediators to the development of
organ dysfunction. Thus, two well established and cur-
rently utilized standards of care for managing the abdom-
inal cavity after source control laparotomies are being
compared, recognizing that all patients will be undergoing
source control laparotomies. Neither method is consid-
ered more efficacious, and multiple extensive reviews of
the existing world literature cannot provide any further
guidance beyond biased opinion [44, 48, 51–53]. Both ap-
proaches offer known and realistic possible risks to the pa-
tient. It is important to note that this patient population
will be very sick, and either therapy can be associated with
dangerous complications during the surgical treatment of
abdominal sepsis.
Requirement 4
The prospective participant is unconscious or lacks cap-
acity to understand the risks, methods and purposes of
the research project;
Any patient being considered for enrollment will only
meet inclusion criteria during the operation: by defin-
ition, they will be under a general anaesthetic and unable
to provide consent. Preoperatively, most of these
patients will also be very ill and, through the nature of
severe sepsis, have diminished mental capacity due to
multi-system organ dysfunction [9, 54, 55]. Sepsis is
often accompanied by an acute encephalopathy which,
when present, not only worsens prognosis but grossly
impairs normal information processing [56, 57]. Various
patterns of brain imaging findings have been described
in adult patients with acute sepsis and include cytotoxic
edema, vasogenic edema, posterior reversible encephal-
opathy syndrome, white matter disruption, and brain
atrophy [54, 58, 59]. Thus, those with SCIAS will have
many threats to the normal cognition, which will typic-
ally require a long period of postoperative convalescence
prior to full neurocognitive recovery. Most patients with
preoperative ‘acute abdomens’ will not meet inclusion
criteria intra-operatively (as SCIAS, and the inclusioncriteria of COOL, specifically define a narrow subset of
patients with intra-abdominal sepsis and evidence of
shock/multi-organ dysfunction). Therefore, preopera-
tively identifying patients, and approaching legally
authorized representatives, are not feasible.
Requirement 5
Third-party authorization cannot be secured in sufficient
time, despite diligent and documented efforts to do so
True study eligibility for COOL will only be finally
ascertained once the patient is in the operating room
with an open peritoneal cavity and the true extent of
intra-peritoneal contamination is appreciated [51]. Due
to the urgent nature of the treatment required in this
population, attempting to obtain surrogate or third-party
authorization would greatly slow patient care and treat-
ment and would certainly prolong the duration of
general anesthetic. Research discussed further below also
supports the contention that a delayed consent paradigm
provides surrogates with the ability to understand trial
information better than when presented in critical
stressful time-pressured situations [57, 60].
Requirement 6
No relevant prior directive by the participant is known
to exist
If such a directive is known, the patient would not be
included in the study. This factor may be more pertinent
in jurisdictions that consider community consultation as
desirable. Unfortunately, SCIAS can afflict any individual
regardless of underlying health, making it difficult to
identify any particular sub-populations of increased risk.
Therefore, emergency consent appears both justified
and required in order to be able to conduct COOL and
to address the research question properly (Fig. 1).
Discussion
All human research must conform to basic principles of
integrity and respect for human dignity. Specific ap-
proaches and regulatory details have varied somewhat
around the world with different national or regional sys-
tems attempting to appropriately balance the competing
requirement of adequate prospective informed consent
against the benefits of conducting challenging clinical re-
search [37, 61]. Largent stressed that the critical philo-
sophical values, typically secured through informed
consent, of respect for patient autonomy and protection
of patient well-being, can still be secured to proceed
with emergency research without initial consent when
certain conditions are met [61]. These conditions are (1)
responsiveness (the experimental intervention must be
responsive to an urgent medical need of the patients),
(2) comparable risk-benefit ratio (the risk-benefit ratio of
the experimental intervention is favorable, and at least
Fig. 1 Operationalization of the COOL Trial Informed Consent Process
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trol, if any), (3) no conflicting preferences (there is no
compelling reason to think that participation in the
research conflicts with enrolled patients’ values or
interests), (4) minimal net risks (nonbeneficial proce-
dures included in the study cumulatively pose no greater
than minimal risk), and (5) prompt consent (consent for
ongoing and additional emergency research interven-
tions is obtained as soon as possible) [61].
Truog and colleagues [62] recommended, applied nar-
rowly and conservatively, that a patient’s general consent
for treatment should serve as authorization for participa-
tion in a clinical trial without seeking separate [a priori]
specific consent if:
1. All the treatments in the trial are offered outside
the trial: a trial comparing 2 therapies that are
already in use.
2. The treatments within each arm of the study
involve similar risks to each other, and not greater
risks compared to other reasonable treatment
alternatives.
3. Clinical equipoise must exist between treatments.
4. No reasonable person should have a preference for
one treatment over another, and this should cover
direct and indirect effects of the treatment. The
‘reasonable-person’ standard is best applied by the
local research ethics board/institution review board.5. Patients should be informed that the institution
uses this standard.
For the purposes of the COOL study, the first 4 of the
above 5 criterion are met. The fifth criterion is perhaps
beyond the scope of an individual clinical trial, but per-
haps the COOL study provides the opportunity for par-
ticipating centres to consider what the standard for
research under similar circumstances should be. Truog
provides examples of research that might be relevant: for
example, 2 approved antibiotics for preoperative prophy-
laxis, whether low-dose anticoagulants improves longev-
ity of intravascular catheters, a study to determine speed
to resumption of spontaneous unassisted breathing
[weaning] in ventilated patients, or in general studies
that fall under the heading of quality improvement [62].
A deferred consent process allows initial enrollment of
incapacitated patients into an approved clinical trial with
the expectation that a valid informed consent will be ob-
tained when the patient regains capacity and can fully
understand and appreciate the details of the proposed re-
search. The enrollment and treatment allocation cannot
be ‘un-done’ but the patient or their legal representatives
can thereafter decline further participation and may have
their data and any biological samples destroyed. This po-
tential enrollment process recognizes that there is contin-
ual tension in balancing the requirements for informed
consent and the need to advance knowledge regarding
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treatment uncertainties [37, 63, 64].
Waiving the need for immediate consent and deferring
consent to the postoperative period avoids delaying or
prolonging emergency interventions whilst ensuring per-
mission for ongoing study participation and use of data.
Many countries around the world including the USA,
Canada, Australia, the UK, and the European Union per-
mit deferred consent [61, 63]. For instance, a deferred
consent process was used in both the land-mark SAFE
trial involving nearly 7000 critically ill patients in 16 aca-
demic tertiary hospitals in Australia and New Zealand
[65], and in the CRASH-II trial of 20211 injured adults
in 274 hospitals in 40 countries [66]. In the UK, a de-
ferred consent process for children has been in place
since 2008, provided that treatment is urgently needed,
urgent action is needed for the purposes of the trial, it is
not reasonably practicable to obtain consent prospect-
ively, and an ethics committee has given approval to the
procedure under which the action is taken [37, 67].
Deferred consent is distinct from surrogate consent, or
consent from a legally authorized representative. There
are concerns regarding the validity of surrogate or LAR
consent in urgent, stressful situations such as clinical
emergencies [37, 68]. Some populations such as the
socioeconomically disadvantaged often lack surrogates.
Therefore, relying on surrogate consent may introduce
selection bias and threaten the internal validity of the re-
search findings [61].
Although such consent processes are quite new, the
limited study of these methods themselves has been fa-
vorable. Gamble and colleagues found there was a higher
rate for emergency as compared with elective enroll-
ments, which they interpreted to suggest that there may
be a greater capacity for informed decision making when
parents of critically ill patients were approached after a
critical medical emergency, in a potentially less stressful
environment [37]. Woolfall also noted that when sur-
veyed after the deferred consent process both parents
and practitioners supported the use of deferred consent,
both in the trial they were involved with and its potential
use in future trials [63]. They did caution, however, that
surrogates were very sensitive to the timing of the de-
ferred consent process [63], which speaks to the need to
consider the potential neurocognitive recovery of COOL
patients, or potential lack thereof [69]. Their work also
revealed that delayed consent allowed surrogates to ex-
press a sense that they could understand trial informa-
tion better than if it was presented earlier when the
context was more stressful, findings applicable to pa-
tients themselves faced with potential decision making
in critical illness [63]. However, it should be noted that
public acceptance of the deferred consent process has
not been universally consistent, and further work isjustified to understand the patient and legally authorized
representative’s perspectives on these issues is warranted
[70]. It is possible that there may be disconnect between
how respondents felt about deferred consent in theory
and how they perceived the process in the real world
[70]. Therefore, all efforts should be made to refine the
consent process in surgical emergencies to both enhance
patient and family comfort but to also allow studies of
potentially life-saving interventions to practically proceed.
It has been stated that ethical practice requires that
there must be a state of clinical equipoise regarding the
merits of the two strategies to be tested, and the trial
must be designed in such a way to make it reasonable to
expect that if the trial is successfully concluded, clinical
equipoise would be disturbed and the results convincing
enough to provide a clear answer to clinicians [36]. With
the increasing, but potentially unwarranted recommen-
dations to utilize the open abdomen in SCIAS [16, 71],
there is somewhat of an urgency to conduct an
appropriate trial. In contrast to more formalized and
recognized approaches to pharmaceutical development,
advances in surgery are often unregulated, unstructured,
and variable. The IDEAL model, however, has attempted
to delineate general stages of surgical development as
constituting the stages of innovation, development, ex-
ploration, assessment, and long-term study [38, 72]. Use
of the open abdomen for SCIAS is currently in the
stages of Exploration and Assessment according to the
IDEAL model [38, 72], depending on the local practices
of an institution. If the opportunity for robust evaluation
of open abdomen is not seized, widespread adoption of
this technique may occur without adequate evidence of
efficacy making future study impossible [38, 41].
Due to the fact that the COOL trial will compare two
standards of care that have complete equipoise in the
surgical community and there is an urgent requirement
for treatment in this patient population, delayed consent
is the safest and only practical way to answer the ques-
tion about which method is the best practice, without
having a negative impact on patient care. The COOL
trial is currently approved by the Conjoint Research
Ethics Board of the University of Calgary (REB-16-1588)
to proceed with a delayed consent process given the
time-sensitive critical nature of decision making. Re-
search ethics will vary throughout the world, and it is
anticipated that various local policies concerning com-
munity consent, waiver of consent, or informed consent
of significant patient proxies will vary among the local
approaches to ensure the COOL trial is performed to
the what is perceived to be the highest ethics standard
in each participating jurisdiction. All participating
Institutions will thus be required to obtain research eth-
ics certification (approval). This paradigm will involve
the highest standards, formally recognizing that the
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Clinical Practice Guidelines and applicable regulatory re-
quirements in all health care systems at all times.
The COOL investigators recognize an obligation to pa-
tients with SCIAS to provide the best care and to conduct
ethical research. The Hippocratic Oath requires physicians
to ‘consider for the benefit of my patients and abstain from
whatever is deleterious and mischievous’ and to ‘give no
deadly medicine to any one if asked, nor suggest any such
counsel’. It has been emphasized that competent and ethical
medicine is social rather than individual in nature. Thus,
progress relies on progressive consensus within the medical
community [36]. However consensus opinions based on
anything less than publicly presented evidence should only
be used to guide patient treatment not hunches or guides
or personal preferences based on anything less [36].
Conclusions
A delayed consent mechanism is a practical and ethical
solution to challenges in research in SCIAS. The ultimate
goal of consent is to balance respect for patient partici-
pants and to permit participation in new and urgently
needed trials such as COOL with a reasonable opportun-
ity for improved outcome and minimal risk of harm.
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